446PDPhase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours

ConclusionsAMG 510 is well tolerated with no DLTs at studied doses. Early results suggest antitumor activity of single-agent AMG 510 in pts with KRASG12C mutant solid tumors. Updated results will be presented.Clinical trial identificationNCT03600883 (ClinicalTrials.gov).Editorial acknowledgementDianne Tomita, MPH, a consultant to Amgen Inc.Legal entity responsible for the studyAmgen Inc.FundingAmgen Inc.DisclosureR. Govindan: Honoraria (self), Advisory / Consultancy: AbbVie; Honoraria (self), Advisory / Consultancy: Genentech; Honoraria (self): Millennium; Honoraria (self): F Hoffman La-Roche; Honoraria (self): Janssen; Advisory / Consultancy: Pfizer; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: EMD Sereno; Advisory / Consultancy: BMS; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Roche; Advisory / Consultancy: Nektar; Advisory / Consultancy: Merck; Advisory / Consultancy: Celgene; Advisory / Consultancy: Adaptimmune; Advisory / Consultancy: Phillips Gilmore; Advisory / Consultancy: GSK; Advisory / Consultancy: Jounce; Advisory / Consultancy: Inivata. M.G. Fakih: Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: Array; Research grant / Funding (self): Novartis; Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Amgen. T.J. Price: Research grant / Funding (self): Amgen. G.S. Falchook: Licensing / Royalties: Wolters Kluwer; Advisory / Consultancy, ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research